03 September 2021 | News
Through absorption-type company split
Image credit: shutterstock
Japan-based Fujifilm Corporation has announced the transfer of the radiopharmaceutical business of Fujifilm Toyama Chemical, a consolidated subsidiary of Fujifilm, to PeptiDream Inc.
Fujifilm has entered into a share transfer agreement with PeptiDream, under which all outstanding shares of the newly established company (the new radiopharmaceutical company), to which Fujifilm Toyama Chemical’s radiopharmaceutical business is succeeded, will be transferred to PeptiDream.
Based on this agreement, Fujifilm will receive a lump sum of 30.5 billion yen and potential contingent payments based on the progress of the succeeded business by PeptiDream. The transfer date is scheduled for March 2022.
Under its medium-term management plan “VISION2023“, Fujifilm is accelerating business growth in healthcare, identifying it as one of its key business fields. Fujifilm is currently expanding its healthcare business in two areas, Medical Systems business that handles medical devices and medical IT, and Life Sciences business that handles Bio CDMO, drug discovery support, and pharmaceutical products.
While optimizing the business portfolio in the Life Sciences business field, Fujifilm has decided that it would be best to transfer FUJIFILM Toyama Chemical's radiopharmaceutical business to PeptiDream for further expansion and growth of such business, which is expected to have synergistic effects on drug discovery in combination with radiopharmaceutical products and PeptiDream’s proprietary peptide drug discovery development technology.